Asston Pharmaceuticals Ltd
Established in 2019, Asston Pharmaceuticals Limited is engaged in the manufacturing and export of pharmaceutical formulations and nutraceutical products under the “Asston” brand.[1]
- Market Cap ₹ 85.6 Cr.
- Current Price ₹ 100
- High / Low ₹ 126 / 96.0
- Stock P/E 22.4
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 36.6 %
- ROE 41.8 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 48.2%
Cons
- Company has high debtors of 358 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Quarterly Results
Figures in Rs. Crores
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Figures in Rs. Crores
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
9.60 | 6.54 | 16.03 | 25.04 | |
9.96 | 5.02 | 12.21 | 19.60 | |
Operating Profit | -0.36 | 1.52 | 3.82 | 5.44 |
OPM % | -3.75% | 23.24% | 23.83% | 21.73% |
0.96 | 0.65 | 0.25 | 0.57 | |
Interest | 0.43 | 0.72 | 0.76 | 0.95 |
Depreciation | 0.01 | 0.04 | 0.06 | 0.04 |
Profit before tax | 0.16 | 1.41 | 3.25 | 5.02 |
Tax % | 31.25% | 25.53% | 25.23% | 23.11% |
0.11 | 1.06 | 2.43 | 3.85 | |
EPS in Rs | 1.57 | 15.14 | 31.00 | 6.14 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 38% |
TTM: | 56% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 226% |
TTM: | 57% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 48% |
Last Year: | 42% |
Balance Sheet
Figures in Rs. Crores
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Equity Capital | 0.70 | 0.70 | 0.78 | 6.27 |
Reserves | 0.23 | 1.29 | 6.40 | 4.76 |
3.31 | 5.24 | 6.82 | 7.25 | |
5.25 | 6.46 | 6.70 | 9.84 | |
Total Liabilities | 9.49 | 13.69 | 20.70 | 28.12 |
0.92 | 1.13 | 0.97 | 0.96 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 |
8.57 | 12.56 | 19.73 | 27.16 | |
Total Assets | 9.49 | 13.69 | 20.70 | 28.12 |
Cash Flows
Figures in Rs. Crores
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
-1.19 | -0.32 | -3.97 | -0.03 | |
0.00 | -0.91 | -0.01 | 0.73 | |
1.29 | 1.21 | 3.86 | -0.51 | |
Net Cash Flow | 0.10 | -0.01 | -0.12 | 0.19 |
Ratios
Figures in Rs. Crores
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Debtor Days | 243.33 | 480.53 | 380.71 | 357.86 |
Inventory Days | 27.24 | 204.29 | 53.91 | 18.59 |
Days Payable | 246.78 | 754.51 | 217.50 | 154.11 |
Cash Conversion Cycle | 23.79 | -69.70 | 217.12 | 222.34 |
Working Capital Days | -12.17 | 43.53 | 162.80 | 178.86 |
ROCE % | 37.14% | 37.78% | 36.62% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
8 Sep - NEWSPAPER PUBLICATION FOR 6TH AGM PURSUANT TO REGULATION 47 OF SEBI (LODR), 2015
- Reg. 34 (1) Annual Report. 6 Sep
- NOTICE AND INTIMATION OF 6TH AGM SCHEDULED ON 29 SEPTEMBER, 2025 6 Sep
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
2 Sep - Received international purchase order from leading pharma player worth USD 301,090 dated 02-09-2025.
- Pursuant To The Provisions Of Regulation 42 Of SEBI (Listing Obligation And Disclosure Requirement) Regulation, 2015 25 Aug
Business Model[1][2]
The company has a diversified model involving:
- Direct manufacturing and marketing of its products
- Contract manufacturing/loan licensing for third-party marketers
- Export sales primarily to African markets